SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., May 11, 2026--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that 12 new data presentations across its ...
To have a drug that has an impact on mortality, it’s of huge interest and a benefit for patients with ILD,’ said rheumatologist Voon Ong, MBBS, PhD, who was not involved in the study.
The pulmonary fibrosis treatment market could grow from $1.3 billion to $2.7 billion by 2035 as newer therapies aim to ...
The use of corticosteroids is linked to a higher risk for mortality in patients with acute exacerbations of idiopathic ...
Anxiety and depression are prevalent in patients with IPF and are linked to increased breathlessness and lower energy levels.
A research team has identified a promising new therapeutic strategy for idiopathic pulmonary fibrosis (IPF), showing that ...
The formulation is being developed in collaboration with United Therapeutics Corporation United Therapeutics made an additional $5 million ...
Researchers at Tulane University have identified a potential new way to treat idiopathic pulmonary fibrosis (IPF), a deadly and currently incurable lung disease that affects more than 3 million people ...
Everyday Health on MSN
Travel tips for idiopathic pulmonary fibrosis
Traveling when you have idiopathic pulmonary fibrosis takes planning, but it’s doable. Experts share tips to help you stay ...
Diffuse parenchymal lung diseases encompass a large number of conditions, with a wide range of causes, clinical manifestations, and imaging and pathological features, as well as variable outcomes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results